gemcitabine + nab-paclitaxel trials for Pancreatic Ductal Adenocarcinoma

All gemcitabine + nab-paclitaxel trials · All Pancreatic Ductal Adenocarcinoma trials

Phase breakdown

Recruiting trials studying gemcitabine + nab-paclitaxel for Pancreatic Ductal Adenocarcinoma

• A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
  NCT07020221 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
  NCT05431270 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer
  NCT05257993 · Phase: Phase 1, Phase 2 · Ages: 19 Years to 79 Years · Sex: All (male and female) · 4 locations

Common questions

How many trials study gemcitabine + nab-paclitaxel for Pancreatic Ductal Adenocarcinoma?

3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.